1/4 📢Calling all T-Dxd prescribers!💉 Out now in Frontiers - Oncology our real-world study on the impact of antiemetic prophylaxis in patients treated with T-DXd highlighted the efficacy of the three-drug regimen (with NK1RA) doi.org/10.3389/fonc.2… Luca Licata, MD Giampaolo Bianchini 🧵👇🏻👇🏻

🙌Just out on @JAMAonc our review on PARPi for #breastcancer Many steps have been made in the last 20 yrs; a vast amount is left waiting to be explored. Great team effort led by Dana-Farber’s Breast Oncology Center and IEO. Link 👉 jamanetwork.com/journals/jamao…

This narrative review summarizes the literature supporting the use of PARP inhibitors for breast cancer treatment, as well as potential future research directions. ja.ma/4ai7lDf

Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 💥It's an excellent review on optimizing the use of ICI in the management of metastatic TNBC👇 OncoAlert cancertreatmentreviews.com/article/S0305-…

How to navigate the practical challenges in immunotherapy for mTNBC - Luca Licata, MD bianchini giuseppe G Curigliano MD PhD Javier Cortes MD PhD Lajos Pusztai oncodaily.com/68690.html #Cancer #CancerTreatment #Immunotherapy #MTNBC #OncoDaily #Oncology

🔥ESMO Presidential Election: Voting opens today! I fully support Giuseppe Curigliano, who will dedicate his passion and determination to serving the ESMO community in this role. esmo.org/about-esmo/how…

Fantastic talk by Giampaolo Bianchini at #ASCO2024 : "Does the Target Matter?" re ADCs. Must say, the insights were top-notch! But full disclosure: I might be a bit biased! 😅 #CancerResearch #ADCs

Just out on JAMA Network Open our study on the fate of immunotherapy trials in breast cancer, led by Marco Mariani Take a look at the terrific job and excellent tweetorial he did 👏 Giampaolo Bianchini Ospedale San Raffaele OncoAlert

🔥 Camizestrant in SERENA-6 study demonstrated highly statistically significant and clinical meaningful ⬆️ PFS A landmark trial in oncology history: shifting treatment based on molecular (not clinical) progression by targeting its biological driver astrazeneca.com/media-centre/p…!

New in Clinical Cancer Research: Neoadj. CT+IO improves pCR, EFS & OS in TNBC, but among those who relapse, most do so early (<24m)—especially in pts with residual disease (see below). Urgent need for trials in this high-risk group: ICI+ADC? ICI+VEGF? Bispecifics? 🔗 doi.org/10.1158/1078-0…

Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer aacrjournals.org/clincancerres/… This analysis of five clinical trials evaluating neoadjuvant chemo-immunotherapy in early-stage triple-negative #BreastCancer (TNBC) highlights that

Don't miss this research brief on the timing of recurrence after neoadjuvant chemo-immunotherapy in early-stage #TripleNegativeBreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/40689866/ Luca Licata, MD Marco Mariani Rebecca Dent Sara Tolaney Erika Hamilton, MD, FASCO YaleBreastCancer Giampaolo Bianchini #BreastCancer #bcsm